Evaxion expands AI-Immunology™ platform into autoimmune diseases

Core Viewpoint - Evaxion A/S is expanding its AI-Immunology™ platform to include the discovery and development of treatments for autoimmune diseases, alongside its existing focus on cancers and infectious diseases, aiming to address high unmet medical needs and enhance partnership opportunities [1][7]. Group 1: Expansion of AI-Immunology™ Platform - The expansion will leverage the scalability of the AI-Immunology™ platform, increasing the range of diseases that can be targeted for new treatments [2]. - Autoimmune diseases are characterized by significant unmet medical needs, presenting substantial partnership potential throughout all stages of drug development [2][7]. Group 2: Strategic Milestones for 2026 - The company has outlined several milestones for 2026, including the introduction of the AI-Immunology™ application for autoimmune diseases in the second half of the year [5][6]. - Other milestones include additional biomarker and immunogenicity data for EVX-01, three-year phase 2 clinical efficacy data for EVX-01, regulatory filing for phase 1 trial of EVX-04, and design and preclinical validation of antigens for EVX-B4, all targeted for the second half of 2026 [6]. Group 3: Financial Outlook - The development of applications for autoimmune diseases is included in Evaxion's cash flow outlook and will not affect its cash runway, which extends into the second half of 2027 [4].